Baroreflex activation therapy with the Barostim device from CVRx has received new CPT codes from the American Medical Association. The codes go into effect in January 2026.

The premixed embolic agent is designed to embolize hypervascular tumors and occlude blood flow in a patient's peripheral blood vessels. It was recalled in April due to safety concerns.

The newly approved system includes a stent, dilation balloon and integrated embolic protection filter. After CMS expanded Medicare coverage for carotid artery stenting in 2023, the procedures are expected to grow more and more common as time goes on. 

A new risk score shows potential to help cardiologists predict the risk of some TAVR complications before they happen, guiding important treatment decisions.

This study adds to growing evidence that e-cigarettes play a significant role in cardiovascular problems, similar to smoking. Researchers hope their work can help lead to new public health policies. 

The new Cordella device from Endotronix, now an Edwards Lifesciences company, uses an implantable device to track the patient's pulmonary artery pressure and other helpful health data.

California-based Route 92 Medical previously announced a funding round worth more than $31 million in November. Now, however, a massive addition from Novo Holdings makes the round worth closer to $82 million. 

Which modality should care teams choose for PCI guidance? While there's an argument to be made for choosing IVUS over OCT, some specialists think the two treatment options are close to equal in terms of patient outcomes.